Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

11.14 -0.24 (-2.11%)
Streaming Delayed Price Updated: 12:45 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Enanta Pharmaceuticals, Inc.
Via Business Wire
4 Analysts Have This To Say About Enanta Pharma
 
Via Benzinga
Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Enanta Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Wondering what's happening in today's after-hours session?
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Let's take a look at the stocks that are in motion in today's session.
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update
The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect. 
Via Stocktwits
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in outpatient adults with acute respiratory syncytial virus (RSV) infection who are... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44.... 
Via Benzinga
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of their outstanding shares is at $165.6 million. 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Friday?
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in September Investor Conferences
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series
From Enanta Pharmaceuticals, Inc.
Via Business Wire
FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection
FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data. 
Via Benzinga
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.